Silver Book Fact

Improvements in QoL from TAVR in SAS patients

Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state) to 6.7 at one year, and 7.4 at four years post procedure.

Kovac J, Schuler G, Gerckens U, et al. Four-Year Experience with CoreValve Transcatheter Heart Valve. EuroInterven. 2016; 12(8): 1039-46. https://www.pcronline.com/eurointervention/105th_issue/volume-12/number-8/169/four-year-experience-with-the-corevalve-transcatheter-heart-valve.html

Reference

Title
Four-Year Experience with CoreValve Transcatheter Heart Valve
Publication
EuroInterven
Publication Date
2016
Authors
Kovac J, Schuler G, Gerckens U, et al
Volume & Issue
Volume 12, Issue 8
Pages
1039-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • In 2010, ~67,500 SAVRs were performed in the U.S.
     
  • Satisfaction with HVD Treatment
    Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).